Allarity Therapeutics

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Allarity Therapeutics (NASDAQ: ALLR ) stock is sliding lower on Friday after announcing a reverse stock split. According to a press release, the company plans to enact a one-for-35 reverse stock split.

Why Is Allarity Therapeutics (ALLR) Stock Down 23% Today?

Lifecore Biomedical Inc

Loyalty Ventures

Use these tips for finding high potential penny stocks The post High-Potential: A Short Guide to Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

High-Potential: A Short Guide to Penny Stock Investing

Asensus Surgical

INVO Bioscience

Penny stocks under $1 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 Under $0.99 To Watch Now

Company anticipates that the c ombination of pan-TKI dovitinib and PARP inhibitor stenoparib may generate synergistic anti-cancer activity

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Allarity Therapeutics (NASDAQ: ALLR ) stock is rising higher on Monday after signing an amended letter agreement with 3i. 3i is a holder of Series A Convertible Preferred Stock and the letter agreement covers the conversion price of those shares.

Why Is Allarity Therapeutics (ALLR) Stock 72% Up Today?

Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Applied UV

Geovax Labs

Understand these tips for investing in penny stocks The post The Do's and Don'ts of Penny Stocks Investing for New Investors  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Do's and Don'ts of Penny Stocks Investing for New Investors

GSX Techedu Inc.

SoFi Technologies

Use these tips to find reliable penny stocks information The post How to Find Reliable Penny Stocks Information  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Reliable Penny Stocks Information

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

Cambridge, MA U.S.A. ( October 11 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the second quarter ended June 30, 2022.

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

Allarity Therapeutics Announces Appointment of New Auditor

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

New strategy align s with ongoing shift in oncology standard - of - care towards combination therapies

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

Board Appoints James G. Cullem, J.D. , to Interim Chief Executive Officer , Joan Y. Brown, CPA , to Interim Chief Financial Officer

Allarity Therapeutics Announces Executive Leadership Transition

Cambridge, MA U.S.A . ( June 15 , 202 2 ) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of Roberto Pili, M.D., as a member of the Company's Scientific Advisory Board (SAB). Dr. Pili is a highly respected oncologist and brings to Allarity deep expertise in renal cancers, as well as the development of targeted therapies for personalized medicine.

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

Cambridge, MA U.S.A. ( May 27 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the first quarter ended March 31, 2022.

Allarity Therapeutics Reports First Quarter 2022 Financial Results

Avadel Pharma

BlackSky Technology

Inovio Pharmaceuticals

BitNile Holdings

Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR

Cambridge, MA U.S.A. ( May 1 8 , 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update” on May 16, 2022, included a typographical error in the section titled “Full Year 2021 and Recent Highlights”, describing the size of the debt cancellation which should have read “$971 thousand” instead of “$971 million.” The corrected paragraph is set forth below:

Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Cambridge, MA U.S.A. ( May 16 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Allarity Therapeutics Provides Update on Dovitinib Program

Press release Cambridge, MA U.S.A . ( February 18 , 202 2 ) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the U.S. Food and Drug Administration (“FDA”) has provided the Company with Refusal to File (“RTF”) letters regarding the new drug application (“NDA”) for dovitinib, and its accompanying pre-market approval (“PMA”) application for the DRP ® -Dovitinib companion diagnostic, for the third-line treatment of metastatic renal cell carcinoma (“mRCC”).

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

News for Allarity Therapeutics Stock (ALLR)